中国肿瘤生物治疗杂志2017，Vol.24Issue(11)：1315-1319,5.DOI:10.3872/j.issn.1007-385x.2017.11.013
阿帕替尼联合替吉奥二线治疗复发转移食管癌疗效的初探
Preliminary exploration about efficacy of apatinib plus S-1 to remedy the patients with recurrent and metastatic esophageal cancer as the 2nd line therapy
帖晓静 1申凤乾 1屈福莲 1张燕 1弋振营 1刘培杰 1高岭 1李宁 1徐志巧1
作者信息
- 1. 河南省开封市中心医院肿瘤科,河南开封475000
- 折叠
摘要
Abstract
Objective:To explore efficacy of apatinib plus S-1 to treat the patients with recurrent and metastatic esophageal cancer as 2nd line therapy and its toxic and side effects.Methods:Twenty-four patients with recurrent and metastatic esophageal cancer who diagnosed and remedied in Department of Oncology,the Central Hospital of Kaifeng during June 2015 to December 2016 were collected.Them were divided into Observation and Control groups.Ten patients in the Observation group took orally apatinib plus S-1 as chemotherapy,apatinib was orally taken in 500 mg/d and S-1 taken according to body surface area for 1 to 14 days.Twenty eight days were as one cycle.Fourteen patients in the Control group were treated with routine S-1.Results:After two cycles,efficacy of the chemotherapy was evaluated as CR 0 case;PR 5 cases;SD 3 cases and PD 2 cases.ORR was 50％ (5/10) and DCR was 80％ (8/10).Before the chemotherapy,baseline diameter sum of 20 target lesions was 71.5 cm,diameter sum of the 20 target lesions became 40.5 cm after 2 cycles of the chemotherapy,and the diameter sum decreased by 43.36％ compared with the baseline diameter sum.After six patients completed 4 cycles of the combination chemotherapy,the patients whose efficacy evaluation were effective or stable continued to take orally apatinib alone for maintenance therapy,the longest PFS of the patients was 9 months and their shortest PFS 6 months.Sever drug-related toxic and side effects didn't be observed.Conclusion:Efficacy of apatinib plus S-1 to treat the patients with recurrent and metastatic esophageal cancer as 2nd line therapy might be better,and its safety and tolerability could be acceptable.关键词
阿帕替尼/替吉奥/食管癌/二线治疗Key words
apatinib/S-1/esophageal cancer/the 2nd line therapy分类
医药卫生引用本文复制引用
帖晓静,申凤乾,屈福莲,张燕,弋振营,刘培杰,高岭,李宁,徐志巧..阿帕替尼联合替吉奥二线治疗复发转移食管癌疗效的初探[J].中国肿瘤生物治疗杂志,2017,24(11):1315-1319,5.
